Castle Biosciences, Inc. (CSTL) financial statements and ratios from SEC XBRL: revenue $0.4B (TTM), net margin -7.0%, revenue growth 3.7% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $344.23M |
| Revenue (TTM) | $0.4B |
| Net Margin | -7.0% |
| Operating Margin (TTM) | -6.4% |
| Net Debt / EBITDA | 1.6 |
| Revenue Growth (YoY) | 3.7% |
| EPS Growth (YoY) | -225.8% |
| FCF Growth (YoY) | -22.5% |
| Price / Book | 2.27 |
| Price / Sales | 3.02 |
| FCF Yield | -8.3% |
| Altman Z-Score | 6.21 (safe) |
| Piotroski F-Score | 3/9 |
| Piotroski checks passed | 3 of 9 |
| Industry P/E (Healthcare Services) | 25.4 |
| Sector P/E (Healthcare) | 21.9 |
CSTL overview · CSTL earnings · CSTL KPIs · CSTL documents · CSTL ownership · CSTL peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.